Antidepressants: Past, Present and Future
Author: Renato D. Alarcón
Publisher: Springer Science & Business Media
Published: 2004-02-19
Total Pages: 644
ISBN-13: 9783540430544
DOWNLOAD EBOOKWith contribution by numerous experts
Read and Download eBook Full
Author: Renato D. Alarcón
Publisher: Springer Science & Business Media
Published: 2004-02-19
Total Pages: 644
ISBN-13: 9783540430544
DOWNLOAD EBOOKWith contribution by numerous experts
Author: Alexander Glassman
Publisher: John Wiley & Sons
Published: 2011-06-20
Total Pages: 110
ISBN-13: 1119957621
DOWNLOAD EBOOKRecently, there has been a growing awareness of the multiple interrelationships between depression and various physical diseases. Patients with psychiatric problems, particularly depression, may be more susceptible to cardiovascular disorders. Depression and Heart Disease synthesizes current evidence, including some previously unpublished data, in a concise, easy-to-read format. The authors succinctly describe the epidemiology, pathogenesis (including cytokines and genetics), and risk factors of the comorbidity between depression and heart disease. The book also reviews the best pharmacological and psychotherapeutic approaches for people with this comorbidity.
Author: Graziano Pinna
Publisher:
Published: 2015-04-01
Total Pages: 412
ISBN-13: 9781634820769
DOWNLOAD EBOOKFluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.
Author: American Psychiatric Association
Publisher: American Psychiatric Publishing
Published: 2021-09-24
Total Pages:
ISBN-13: 9781955245180
DOWNLOAD EBOOKAuthor: David Mrazek
Publisher: Oxford University Press
Published: 2010-06-10
Total Pages: 276
ISBN-13: 0195367294
DOWNLOAD EBOOKPsychiatric Pharmacogenomics is a book written to help clinicians to use pharmacogenomic testing to improve the pharmacotherapy that they provide for their patients. It is designed to teach clinicians how to order pharmacogenomic tests and interpret the results. Clinical examples are used to underscore the specific indications for pharmacogenomic testing and to clarify the clinical usefulness of identifying atypical genotypes that result in problematic responses to medication. The first section of the book begins with a basic review of molecular genetics. Additionally, the book also includes an extensive glossary of technical terms associated with molecular genetics and pharmacogenomics. The clinical utility of pharmacogenomic testing is demonstrated throughout the book by describing the implications of genetic variations for the care of individual patients. The second section of the book is organized into fourteen chapters that each focus on the clinical implications of testing for specific genes for which variants have been associated with either therapeutic response or side effects of psychotropic medications. Each of these chapters is structured in the same manner and involves a description of the gene and its significant variants. Each chapter also includes one or more clinical vignettes. The third section of the book discusses the clinical usefulness of pharmacogenomic testing, ethical issues associated with pharmacogenomic testing, and provides predictions for the future development of more sophisticated pharmacogenomic testing.
Author: Peter Riederer
Publisher: Springer Nature
Published: 2022-11-04
Total Pages: 4652
ISBN-13: 303062059X
DOWNLOAD EBOOKThis book provides a reference guide describing the current status of medication in all major psychiatric and neurological indications, together with comparisons of pharmacological treatment strategies in clinical settings in Europe, USA, Japan and China. In addition, it highlights herbal medicine as used in China and Japan, as well as complementary medicine and nutritional aspects. This novel approach offers international readers a global approach in a single dedicated publication and is also a valuable resource for anyone interested in comparing treatments for psychiatric disorders in three different cultural areas. There are three volumes devoted to Basic Principles and General Aspects, offering a general overview of psychopharmacotherapy (Vol. 1); Classes, Drugs and Special Aspects covering the role of psychotropic drugs in the field of psychiatry and neurology (Vol. 2) and Applied Psychopharmacotherapy focusing on applied psychopharmacotherapy (Vol. 3). These books are invaluable to psychiatrists, neurologists, neuroscientists, medical practitioners and clinical psychologists.
Author: Peter Nathan
Publisher: Oxford University Press
Published: 2002-01-18
Total Pages: 705
ISBN-13: 0199760985
DOWNLOAD EBOOKA fully revised and updated edition of this unique and authoritative reference The award-winning A Guide to Treatments that Work , published in 1998, was the first book to assemble the numerous advances in both clinical psychology and psychiatry into one accessible volume. It immediately established itself as an indispensable reference for all mental health practitioners. Now in a fully updated edition,A Guide to Treatments that Work, Second Edition brings together, once again, a distinguished group of psychiatrists and clinical psychologists to take stock of which treatments and interventions actually work, which don't, and what still remains beyond the scope of our current knowledge. The new edition has been extensively revised to take account of recent drug developments and advances in psychotherapeutic interventions. Incorporating a wealth of new information, these eminent researchers and clinicians thoroughly review all available outcome data and clinical trials and provide detailed specification of methods and procedures to ensure effective treatment for each major DSM-IV disorder. As an interdisciplinary work that integrates information from both clinical psychology and psychiatry, this new edition will continue to serve as an essential volume for practitioners of every kind: psychiatrists, psychologists, clinical social workers, counselors, and mental health consultants.
Author:
Publisher: Academic Press
Published: 2019-07-13
Total Pages: 290
ISBN-13: 0128173173
DOWNLOAD EBOOKDrug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series
Author: Irving Kirsch
Publisher: Basic Books
Published: 2010-01-26
Total Pages: 242
ISBN-13: 0465021042
DOWNLOAD EBOOKDo antidepressants work? Of course -- everyone knows it. Like his colleagues, Irving Kirsch, a researcher and clinical psychologist, for years referred patients to psychiatrists to have their depression treated with drugs before deciding to investigate for himself just how effective the drugs actually were. Over the course of the past fifteen years, however, Kirsch's research -- a thorough analysis of decades of Food and Drug Administration data -- has demonstrated that what everyone knew about antidepressants was wrong. Instead of treating depression with drugs, we've been treating it with suggestion. The Emperor's New Drugs makes an overwhelming case that what had seemed a cornerstone of psychiatric treatment is little more than a faulty consensus. But Kirsch does more than just criticize: he offers a path society can follow so that we stop popping pills and start proper treatment for depression.
Author: George G. Nomikos
Publisher: Academic Press
Published: 2019-06-18
Total Pages: 460
ISBN-13: 0128031646
DOWNLOAD EBOOKTranslational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders. Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans. - Includes comprehensive coverage of biomarker tools and the role of personalized medicine in CNS drug development - Discusses strategies for drug development for a full range of CNS indications, with particular attention to neuropsychiatric and neurocognitive disorders - Includes chapters written by international experts from industry and academia